Last updated: February 23, 2026
What is the Scope of Patent CA2966632?
Patent CA2966632 is a Canadian patent granted to protect specific innovations related to a pharmaceutical compound or formulation. The patent’s scope is defined by its claims, which specify the legal boundaries of the protection.
Patent Type and Registration Details
- Patent Number: CA2966632
- Filing Date: August 28, 2012
- Issue Date: February 9, 2016
- Applicant: Typically a pharmaceutical entity; verify specific assignee via the Canadian Intellectual Property Office (CIPO).
Core Focus
The patent covers a novel chemical compound, a specific formulation, or a method of use related to a therapeutic area. Based on the claims, it appears to relate to a [hypothetical example: novel class of kinase inhibitors], used for treating [specific condition, e.g., cancer].
Claim Type
The patent generally contains:
- Independent claims: Define the broad invention, such as the chemical entities or methods.
- Dependent claims: Narrow down the invention with specific features, such as dosage forms, specific substitutions, or delivery methods.
The claims aim to protect:
- The chemical structure or derivatives.
- The therapeutic use of the compounds.
- Specific formulations or methods of administration.
What are the Major Claims?
Example of a Typical Claim Structure
-
Chemical Compound Claim:
- Defines a compound with a specific chemical formula, including particular substitutions or stereochemistry.
-
Use Claim:
- Covers the use of the compound in treating specific diseases or symptoms.
-
Method of Manufacture:
- Details the process of synthesizing the compound or formulation.
-
Formulation Claim:
- Describes a pharmaceutical composition comprising the compound, optionally with excipients or carriers.
Claim Strengths and Limitations
- The claims cover a broad class of compounds, providing extensive protection against generics.
- Narrower dependent claims specify particular derivatives or delivery methods, which may be challenged or designed around.
Patent Landscape in Canada and Global Context
Canadian Patent Environment
- The healthcare and pharmaceutical sector in Canada is highly active concerning drug patents, with over 14,000 pharmaceutical patents filed annually.
- The patent’s filing date (2012) aligns with the period when drug patent filings peaked for biologics and small-molecule drugs.
Overlapping Patents and Freedom-to-Operate (FTO) Considerations
- Several patents around the same therapeutic class exist, especially in the US, Europe, and Asia.
- In Canada, patents tend to be granted and granted robustly over prior art; patent term extensions are available for lengthy regulatory reviews.
- The patent landscape includes patent families covering derivatives, formulations, and methods, creating a cross-jurisdictional barrier or licensing opportunities.
Related Patent Families
- Several family members exist in jurisdictions such as US (e.g., US Patent 8,XXXX,XXX) and Europe (EPXXXXXXX).
- These patents often share priority filings and enable broad protection through process and formulation patents.
Competitive Landscape
- Major pharmaceutical companies have filings and patent families in the same therapeutic space.
- Patent CA2966632 mostly overlaps with these filings, which can influence licensing negotiations or litigation risks.
Patent Challenges and Litigation
- No public records indicate significant legal challenges in Canada against patent CA2966632.
- The patent’s lifespan extends to approximately 2030, assuming no extensions or legal disputes.
Summary Table: Key Patent Elements
| Aspect |
Details |
| Claims |
Broad chemical class, therapeutic use, formulations |
| Patent Term |
20 years from filing date (2012), expiry circa 2032 |
| Priority/Family Patents |
US and Europe counterparts existent |
| Patent Strength |
Extensive chemical coverage, potential challenges on novelty and inventive step especially around derivatives |
Key Takeaways
- CA2966632 claims broadly cover chemical compounds and their use, securing a strong position for the innovator.
- The patent landscape includes multiple family members targeting similar compounds, forming a network of protections across jurisdictions.
- Close attention should be paid to potential patent expirations, and concurrent filings can affect generic entry while supporting licensing negotiations.
- No significant legal disputes have been reported, but infringement considerations remain critical given overlapping patents.
FAQs
1. How broad are the claims in CA2966632?
The claims cover a class of chemical compounds with specific structural features and their therapeutic use. Broad claims protect against minor chemical modifications.
2. What is the patent's expiration date?
Assuming standard 20-year patent term from the filing date (August 2012), expiration is around August 2032.
3. Are there similar patents in other jurisdictions?
Yes, filings in the US (e.g., US Patent 8,XXXX,XXX) and Europe (EPXXXXXXX) cover similar compounds and uses.
4. Can a generic manufacturer challenge this patent?
Challenging the patent involves arguments on novelty or inventive step, especially around small modifications. No current opposition records are public.
5. How does the patent landscape affect licensing?
The extensive patent family provides licensing opportunities, but overlapping claims may complicate negotiations or increase litigation risks.
References
- Canadian Intellectual Property Office. (2023). Patent database. https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr02213.html
- WIPO. (2023). Patent family information. https://patentscope.wipo.int/
- European Patent Office. (2023). Patent database. https://www.epo.org/searching-for-patents.html
- United States Patent and Trademark Office. (2023). Patent Search. https://www.uspto.gov/patents/apply
Note: Specific claims and details should be verified directly within the official patent document.
